Abstract
Natural products have unique therapeutic effects in the treatment of various diseases. Ginseng, as a traditional Chinese herb, is effective against a wide range of diseases. Nowadays, studies have shown that ginsenoside RG3, the active ingredient of ginseng, has obvious anti-tumor effects. However, since the drug concentration is too low when the drug is administered orally to reach ovarian cancer (OC), this study aims to develop a new way of RG3 administration. Microneedles (MNs), which are made of methacryloyl gelatin and have good biocompatibility and drug-carrying efficiency, were employed to deliver RG3 directly to the surface of ovarian tumors. RG3 was encapsulated in MNs, and RG3-MNs could effectively penetrate the tumor tissue and release the drug with ideal kinetics. In vivo and in vitro experiments demonstrated the anti-tumor efficiency and biosafety of RG3-MNs. RG3-MNs could inhibit the proliferation of OC cells and promote apoptosis, thus exerting anti-tumor effects. These results indicated that loading RG3-MNs has good prospects in the clinical therapy of OC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
